Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9339364 | 0.86 | KMT2A (0.56) | CES2CES1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL2060208 | 0.82 | CYP4F2 (0.48) | CYP4F2CYP4A11CES2CES1KMT2A | |
| SCHEMBL9340141 | 0.81 | KMT2A (0.69) | KMT2ASMN1; SMN2MAPTMEN1TDP1 | |
| SCHEMBL4798869 | 0.80 | CES2 (0.53) | CES2CES1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL27852004 | 0.80 | ESR1 (0.67) | KMT2ASMN1; SMN2MAPTMEN1TDP1 | |
| SCHEMBL10728499 | 0.80 | CYP4F2 (0.51) | CYP4F2CYP4A11TDP1CYP3A4NPC1 | |
| SCHEMBL2060065 | 0.78 | KMT2A (0.49) | KMT2ASMN1; SMN2MAPTMEN1TDP1 | |
| SCHEMBL5706002 | 0.77 | KMT2A (0.63) | KMT2ASMN1; SMN2MAPTMEN1ESR1 | |
| SCHEMBL7616356 | 0.76 | CES2 (0.59) | CES2CES1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL8491879 | 0.75 | EGFR (0.47) | KMT2ASMN1; SMN2MAPTMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446388-B1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | STERIX LTD (GB) | 2013-01-09 | — | — | EP | disclosed |
| US-8148415-B2 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148415-B2 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148415-B2 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2012-04-03 | — | — | US | disclosed |
| US-7745472-B2 | Compound | STERIX LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745472-B2 | Compound | STERIX LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20090111862-A1 | Compound | RICHTER GEDEON NYRT. (HU) | 2009-04-30 | — | — | US | disclosed |
| US-20090111862-A1 | Compound | RICHTER GEDEON NYRT. (HU) | 2009-04-30 | — | — | US | disclosed |
| US-7361677-B2 | Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase | STERIX, LTD. (GB) | 2008-04-22 | — | — | US | disclosed |
| US-7361677-B2 | Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase | STERIX, LTD. (GB) | 2008-04-22 | — | — | US | disclosed |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| EP-1765792-A1 | SULFAMIC ACID ESTER COMPOUNDS USEFUL IN THE INHIBITION OF STEROID SULPHATASE ACTIVITY AND AROMATASE ACTIVITY | Sterix Limited (GB) | 2007-03-28 | — | — | EP | disclosed |
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STERIX LTD. | 2006-10-26 | — | — | US | disclosed |
| WO-2005115996-A1 | SULFAMIC ACID ESTER COMPOUNDS USEFUL IN THE INHIBITION OF SEROID SULPHATASE ACTIVITY AND AROMATASE ACTIVITY | STERIX LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111862-A1 | Compound | QPCT, SQOR, SDHA | CYP4F2 247/4885CYP4A11 1242/4885CES2 1814/4885 |
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STS, SULT1E1, CYP19A1 | CYP4F2 629/4885CYP4A11 470/4885CES2 1236/4885 |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STS, SULT1E1, CYP19A1 | CYP4F2 67/4885CYP4A11 56/4885CES2 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.